Article ID Journal Published Year Pages File Type
5701603 Journal of Thoracic Oncology 2017 31 Pages PDF
Abstract
EGFR TKIs are well tolerated, with less than 10% of patients discontinuing treatment because of AEs. The profile of and risk for toxicities vary between EGFR TKIs and can be used to inform the selection of treatment.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Authors
, , , , , , , ,